Tip os
Log ind
Henrik Jacobi2.jpg

ALK-director: Important strategic approval

Top picks in English:

With the expansion of the indication for their house dust mite pill, which now also covers the age range from 12-17 years, ALK gets access to a strategically important market segment.


BY LOUISE WENDT JENSEN
Offentliggjort 19.04.17 kl. 14:38

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo chief: ”This is data the world has never seen before”

Mads Krogsgaard Thomsen Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Leo’s bet on biologics progresses as planned

Top picks in English:

The biotech company Argenx has finished the preclinical work with the drug Leo Pharma invested in. Next stop is phase I “Our bet on biologics looks promising,” says Leo Pharma R&D chief.

Lundbeck executive: I knew FDA had another opinion

Top picks in English:

It is yet uncertain whether Lundbeck, for the third time, will try to win an updated label for antidepressant Trintellix in the US, says Anders Gersel Pedersen, Lundbeck’s executive vice president for research and development. Last week's rejection from FDA came as no surprise to him.

Lundbeck has found its new CEO

Top picks in English:

The Danish pharmaceutical group Lundbeck has finally appointed a new CEO to follow ousted Ulf Wiinberg. The new chief is a Danish national and recently departed Novo Nordisk-exec.

Novo to actively enter potential multi-billion-dollar market

Top picks in English:

Novo Nordisk said in its annual report that the company expects to actively enter the market for treatments against non-alcoholic steatohepatitis (NASH), a market that is expected to generate billions of dollars in revenue in the not too distant future.

Forsiden lige nu

Mercks lægemiddelhåb løber ind i nye problemer

POLFOTO_43540375.jpg Medicinal & Biotek:

Immunterapien Keytruda fra amerikanske Merck har misset det primære effektmål i et studie i hoved- og halskræft. Det er endnu et tilbageslag for selskabets absolut største lægemiddelhåb.

Diabetesmidler sikrer solid vækst for Eli Lilly

Medicinal & Biotek:

Eli Lillys omsætning stiger pænt i andet kvartal, mens der lægges en tredjedel til bundlinjen. Det skyldes i høj grad salget af diabeteslægemidler, særligt GLP-1-analogen Trulicity, som lægger pres på Novo Nordisk. Forventningerne til helåret hæves.

Biogen løfter forventningerne

Medicinal & Biotek:

Amerikanske Biogen hæver sine forventninger til salget i 2017 efter et kvartal, hvor skleroseblockbusteren Tecfidera solgte for mere en 1 mia. dollars, mens muskelsvindsmidlet Spinraza også leverede varen.

Udenlandske medicinalkæmper lukrerer på manglende konkurrence i Danmark

Medicinal & Biotek:

Det seneste år har det været en overordentlig god forretning at sælge en speciel type hjertemedicin i Danmark, for der har kun været to aktører på markedet. Resultatet illustrerer svagheden på et medicinmarked med for få aktører, mener apoteker.

Importører tilbagekalder forfalskede medicinpakninger

Medicinal & Biotek:

Tre danske parallelimportører har bedt apoteker fjerne en batch af skizofrenimidlet Xeplion 150 mg fra hylderne på grund af mistanke om forfalskning.

Danmarks største medicinalgrossist har vendt dalende overskud

Medicinal & Biotek:

Der er fremgang over hele linjen hos landets største medicinalgrossist Nomeco, der efter to år med faldende overskud igen går frem.

ANNONCE
ANNONCE


ANNONCE